Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin H Kim

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|April 9, 2026
Biologics and Novel Therapeutics in Food AllergyBrent Anderson, Claire Pascal, M Gohazrua K Butler, et al.
Lancet (London, England)|January 23, 2022
Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled studyStacie M Jones, Edwin H Kim, Kari C Nadeau, et al.
Science Translational Medicine|November 16, 2022
Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergensElise G Liu, Biyan Zhang, Victoria Martin, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 6, 2026
Management of gastrointestinal symptoms during oral immunotherapy: Guidance from OUtMATCH InvestigatorsSayantani B Sindher, Mirna Chehade, Evan S Dellon, et al.
The Journal of Allergy and Clinical Immunology. Global|October 2, 2023
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)Robert A Wood, R Sharon Chinthrajah, Amanda K Rudman Spergel, et al.
JAMA|February 23, 2019
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical TrialDavid M Fleischer, Matthew Greenhawt, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The New England Journal of Medicine|February 26, 2024
Omalizumab for the Treatment of Multiple Food AllergiesRobert A Wood, Alkis Togias, Scott H Sicherer, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 1, 2021
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsJacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2020
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year resultsDavid M Fleischer, Wayne G Shreffler, Dianne E Campbell, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
The Journal of Allergy and Clinical Immunology. in Practice|April 9, 2026
Biologics and Novel Therapeutics in Food AllergyBrent Anderson, Claire Pascal, M Gohazrua K Butler, et al.
Lancet (London, England)|January 23, 2022
Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled studyStacie M Jones, Edwin H Kim, Kari C Nadeau, et al.
Science Translational Medicine|November 16, 2022
Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergensElise G Liu, Biyan Zhang, Victoria Martin, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 6, 2026
Management of gastrointestinal symptoms during oral immunotherapy: Guidance from OUtMATCH InvestigatorsSayantani B Sindher, Mirna Chehade, Evan S Dellon, et al.
The Journal of Allergy and Clinical Immunology. Global|October 2, 2023
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)Robert A Wood, R Sharon Chinthrajah, Amanda K Rudman Spergel, et al.
JAMA|February 23, 2019
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical TrialDavid M Fleischer, Matthew Greenhawt, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The New England Journal of Medicine|February 26, 2024
Omalizumab for the Treatment of Multiple Food AllergiesRobert A Wood, Alkis Togias, Scott H Sicherer, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 1, 2021
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsJacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2020
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year resultsDavid M Fleischer, Wayne G Shreffler, Dianne E Campbell, et al.
Pageof 10